Outset Medical, Inc.

Outset is a medical technology company that has developed the Tablo® Hemodialysis System (Tablo), a technology designed to improve dialysis outcomes while reducing cost and complexity. Tablo is a single enterprise solution intended for use across various care settings, enabling dialysis to be delivered in hospitals, clinics, or at home. The U.S. Food and Drug Administration (FDA) has cleared Tablo for these uses. The system operates using only an electrical outlet and tap water, eliminating the need for the extensive infrastructure typically required by traditional dialysis machines. Tablo integrates water purification and on-demand dialysate production within a single 35-inch compact console. It utilizes cloud technology, allowing providers to remotely monitor devices and treatments, conduct patient and population analytics, and automate clinical recordkeeping. The system features a simple-to-use touchscreen interface and two-way wireless data transmission, supported by a proprietary data analytics platform. Unlike traditional hemodialysis machines, Tablo offers clinical versatility across multiple care settings and a broad range of clinical applications. Studies and surveys have indicated that Tablo can lead to significant operational efficiencies for providers, including reduced costs for dialysis programs, and has demonstrated robust clinical care. Patients using Tablo have reported quality of life benefits compared to other dialysis machines.